MELD scoreModel for End-Stage Liver Diseaseserum bilirubinserum creatinineINR

MELD Score: Calculation and Clinical Application

MELD Score: Calculation and Clinical Application

The Model for End-Stage Liver Disease (MELD) is a critical clinical tool used to predict the survival of patients with advanced liver disease. By analyzing specific laboratory values, healthcare providers can objectively assess the severity of a patient's condition, which is essential for prioritizing organ transplants and managing care.

How the MELD Score is Determined

The MELD score is derived from three primary laboratory measurements that reflect the liver's function and the body's overall health: serum bilirubin (a byproduct of red blood cell breakdown), serum creatinine (a waste product indicating kidney function), and the International Normalized Ratio (INR), which measures the time it takes for blood to clot (prothrombin time).

The score is calculated using the following mathematical formula:

MELD = 3.78 × ln(serum bilirubin (mg/dL)) + 11.2 × ln(INR) + 9.57 × ln(serum creatinine (mg/dL)) + 6.43

Because the formula uses natural logarithms (ln), the final result is rounded to the nearest whole number for reporting purposes.

[ไม่มีภาพประกอบ]

UNOS Modifications and Scoring Rules

The United Network for Organ Sharing (UNOS) has implemented specific modifications to ensure the score remains accurate and fair across different patient scenarios:

  • Minimum Value Rule: To prevent the natural logarithm from producing a negative value (which occurs when a number is between 0 and 1), any laboratory value less than 1.0 is automatically assigned a value of 1.0. For example, if a patient's bilirubin is 0.8 mg/dL, 1.0 is used in the calculation.
  • Dialysis Adjustment: If a patient has undergone dialysis at least twice within the previous seven days, the serum creatinine value is set to 4.0 mg/dL regardless of the actual lab result.

Evolution of the MELD Model

Originally, the etiology (the underlying cause) of the liver disease was included in the model. However, this was later removed because categorizing patients with multiple causes of liver disease proved too difficult. Research indicated that removing the etiology did not significantly impact the model's ability to predict three-month survival rates.

Additionally, patients diagnosed with liver cancer are assigned a MELD score based on the clinical advancement of their cancer.

Key Facts

  • MELD predicts survival based on bilirubin, creatinine, and INR.
  • Scores are reported as rounded whole numbers.
  • Values below 1.0 are treated as 1.0 to avoid negative logarithmic results.
  • Patients with recent dialysis (2+ times in 7 days) are assigned a creatinine value of 4.0 mg/dL.
  • The cause of liver disease is no longer part of the calculation.
Component Measurement Clinical Significance
Serum Bilirubin mg/dL Liver excretion function
INR Ratio Blood clotting/Protein synthesis
Serum Creatinine mg/dL Kidney function

Frequently Asked Questions

What happens if a lab value is less than 1?

Any value less than 1 is assigned a value of 1.0. This is done because the natural logarithm of a number between 0 and 1 is negative, which would incorrectly subtract from the total score.

How is dialysis handled in the MELD calculation?

If a patient has been dialyzed twice or more within the last seven days, their serum creatinine is automatically set to 4.0 mg/dL for the purpose of the calculation.

Is the cause of the liver disease included in the score?

No, the etiology of the liver disease was removed from the model because it was difficult to categorize patients with multiple causes and did not significantly change the accuracy of three-month survival predictions.

How are patients with liver cancer scored?

Patients with liver cancer are assigned a MELD score based on the stage or advancement of their cancer.

Why is the MELD score rounded?

MELD scores are reported as whole numbers to provide a clear, standardized metric for clinical use and transplant prioritization.

References

  1. Malinchoc, Michael; Kamath, Patrick S; Gordon, Fredric D; Peine, Craig J; Rank, Jeffrey; Ter Borg, Pieter C.J (2000). "A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts". Hepatology. 31 (4): 864–71. doi:10.1053/he.2000.5852. PMID 10733541.
  2. Kamath, P; Wiesner, R. H; Malinchoc, M; Kremers, W; Therneau, T. M; Kosberg, C. L; d'Amico, G; Dickson, E. R; Kim, W. R (2001). "A model to predict survival in patients with end-stage liver disease". Hepatology. 33 (2): 464–70. doi:10.1053/jhep.2001.22172. PMID 11172350. S2CID 72518575.
  3. Kamath, Patrick S; Kim, W. Ray (2007). "The model for end-stage liver disease (MELD)". Hepatology. 45 (3): 797–805. doi:10.1002/hep.21563. PMID 17326206.
  4. Jung, G.E; Encke, J; Schmidt, J; Rahmel, A (2008). "Model for end-stage liver disease". Der Chirurg. 79 (2): 157–63. doi:10.1007/s00104-008-1463-4. PMID 18214398. S2CID 25562795.
  5. UNOS (2009-01-28). "MELD/PELD calculator documentation" (PDF). Retrieved 2010-02-21.